arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Viking Therapeutics, Inc.

VKTX
$33.30 ▼ -0.23 (-0.70%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
51 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Viking Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.9B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -25.7%
FCF / Share $-1.08
Trailing P/E
Price / Book 9.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-128.02M
↓ -95.3%
FCF / Share Free cash flow per share
$-1.08
↓ -9.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Cash Quality
52

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 51 quarters